Von Eschenbach attacked from both sides
This article was originally published in The Gray Sheet
Executive Summary
Conservatives, including Concerned Women for America and the National Pro-Life Action Center, call for the withdrawal of FDA Acting Commissioner Andrew von Eschenbach's nomination to head the agency in reaction to FDA signals that it might be moving toward approving over-the-counter status for Barr Pharmaceutical's Plan B emergency contraceptive. The firm plans to resubmit its OTC application by the end of the month after an Aug. 8 meeting with the agency. Meanwhile, Sens. Hilary Clinton (D-N.Y.) and Patty Murray (D-Wash.), who support the OTC switch, said July 31 they will maintain their hold on von Eschenbach's nomination until the agency makes a decision (1"The Gray Sheet" Aug. 7, 2006, p. 17)...
You may also be interested in...
Von Eschenbach Nomination Still Stalled After Some Movement On Plan B
Senators Hilary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) will maintain their hold on Andrew von Eschenbach's nomination to head FDA, despite what von Eschenbach calls an "important decision" regarding Barr Laboratories' application to offer its Plan B emergency contraceptive over the counter (OTC)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.